EP1366061A4 - Methode de traitement de troubles de la maturation du precurseur de la proteine beta amyloide - Google Patents

Methode de traitement de troubles de la maturation du precurseur de la proteine beta amyloide

Info

Publication number
EP1366061A4
EP1366061A4 EP02718903A EP02718903A EP1366061A4 EP 1366061 A4 EP1366061 A4 EP 1366061A4 EP 02718903 A EP02718903 A EP 02718903A EP 02718903 A EP02718903 A EP 02718903A EP 1366061 A4 EP1366061 A4 EP 1366061A4
Authority
EP
European Patent Office
Prior art keywords
amyloid beta
beta precursor
treating amyloid
disorders
precursor disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02718903A
Other languages
German (de)
English (en)
Other versions
EP1366061A2 (fr
Inventor
Lawrence Friedhoff
Joseph Buxbaum
Edward I Cullen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Corp
Original Assignee
Andrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Corp filed Critical Andrx Corp
Publication of EP1366061A2 publication Critical patent/EP1366061A2/fr
Publication of EP1366061A4 publication Critical patent/EP1366061A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02718903A 2001-02-05 2002-02-05 Methode de traitement de troubles de la maturation du precurseur de la proteine beta amyloide Withdrawn EP1366061A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26588601P 2001-02-05 2001-02-05
US265886P 2001-02-05
PCT/US2002/003256 WO2002062824A2 (fr) 2001-02-05 2002-02-05 Methode de traitement de troubles de la maturation du precurseur de la proteine ? amyloide

Publications (2)

Publication Number Publication Date
EP1366061A2 EP1366061A2 (fr) 2003-12-03
EP1366061A4 true EP1366061A4 (fr) 2006-04-26

Family

ID=23012272

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02718903A Withdrawn EP1366061A4 (fr) 2001-02-05 2002-02-05 Methode de traitement de troubles de la maturation du precurseur de la proteine beta amyloide

Country Status (3)

Country Link
EP (1) EP1366061A4 (fr)
CA (1) CA2437480A1 (fr)
WO (1) WO2002062824A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
AU2004260632A1 (en) 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20070161700A1 (en) 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
JPWO2005063294A1 (ja) * 2003-12-30 2007-12-13 興和株式会社 γ−セクレターゼ複合体形成阻害剤
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
US10821133B2 (en) 2017-12-28 2020-11-03 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN111868232B (zh) 2017-11-22 2024-05-28 Hdl治疗公司 用于对血浆处理系统的流体回路进行灌注的系统和方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006470A1 (fr) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention et traitement de la maladie d'alzheimer
EP0783104A1 (fr) * 1995-12-27 1997-07-09 Oriental Yeast Co., Ltd. Procédé de dosage du précurseur de l'amyloide
WO1997048391A2 (fr) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methodes et compositions a base de r-ibuprofene
WO1998013488A2 (fr) * 1996-09-24 1998-04-02 Schering Aktiengesellschaft Procede pour determiner les modulateurs de la secretase de l'app et utilisation de ces derniers comme agents dans le traitement de la maladie d'alzheimer
WO1998019169A1 (fr) * 1996-10-31 1998-05-07 Trustees Of Boston University Methode diagnostique pour la detection de la maladie d'alzheimer chez des patients vivants
WO1999021978A1 (fr) * 1997-10-28 1999-05-06 The Miriam Hospital, A Lifespan Partner Modele animal non transgenique de la maladie d'alzheimer
WO1999038498A1 (fr) * 1998-01-28 1999-08-05 Warner-Lambert Company Procede pour le traitement de la maladie d'alzheimer
WO1999048488A2 (fr) * 1998-03-23 1999-09-30 Children's Medical Center Corporation ABAISSEMENT DE LA TENEUR EN PROTEINE β-AMYLOÏDE
WO2000028981A2 (fr) * 1998-11-13 2000-05-25 Nymox Corporation Methodes de traitement, de prevention et de reduction du risque d'apparition de la maladie d'alzheimer utilisant un inhibiteur de la hmg-coa reductase
WO2000031548A1 (fr) * 1998-11-25 2000-06-02 Scios Inc. Prevention et traitement de troubles associes aux proteines amyloides
WO2001032161A2 (fr) * 1999-11-04 2001-05-10 Andrx Corporation Methode de traitement de troubles lies au precurseur beta-amyloide

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006470A1 (fr) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention et traitement de la maladie d'alzheimer
EP0783104A1 (fr) * 1995-12-27 1997-07-09 Oriental Yeast Co., Ltd. Procédé de dosage du précurseur de l'amyloide
WO1997048391A2 (fr) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methodes et compositions a base de r-ibuprofene
WO1998013488A2 (fr) * 1996-09-24 1998-04-02 Schering Aktiengesellschaft Procede pour determiner les modulateurs de la secretase de l'app et utilisation de ces derniers comme agents dans le traitement de la maladie d'alzheimer
WO1998019169A1 (fr) * 1996-10-31 1998-05-07 Trustees Of Boston University Methode diagnostique pour la detection de la maladie d'alzheimer chez des patients vivants
WO1999021978A1 (fr) * 1997-10-28 1999-05-06 The Miriam Hospital, A Lifespan Partner Modele animal non transgenique de la maladie d'alzheimer
WO1999038498A1 (fr) * 1998-01-28 1999-08-05 Warner-Lambert Company Procede pour le traitement de la maladie d'alzheimer
WO1999048488A2 (fr) * 1998-03-23 1999-09-30 Children's Medical Center Corporation ABAISSEMENT DE LA TENEUR EN PROTEINE β-AMYLOÏDE
WO2000028981A2 (fr) * 1998-11-13 2000-05-25 Nymox Corporation Methodes de traitement, de prevention et de reduction du risque d'apparition de la maladie d'alzheimer utilisant un inhibiteur de la hmg-coa reductase
WO2000031548A1 (fr) * 1998-11-25 2000-06-02 Scios Inc. Prevention et traitement de troubles associes aux proteines amyloides
WO2001032161A2 (fr) * 1999-11-04 2001-05-10 Andrx Corporation Methode de traitement de troubles lies au precurseur beta-amyloide

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, YANG L B ET AL: "Amyloid beta peptide (Abeta) induced TNF-alpha release from Alzheimer microglia is inhibited by diclofenac, an anti-inflammatory drug", XP002369758, Database accession no. PREV200100121209 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, WESTERMAN M A ET AL: "Ibuprofen as a treatment of cognitive decline in the Tg2576 mouse model of Alzheimer's disease", XP002369757, Database accession no. PREV200100563487 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1998, NETLAND E E ET AL: "Indomethacin reverses the microglial response to amyloid [beta]-protein", XP002369759, Database accession no. EMB-1998240403 *
DOVEY H F ET AL: "FUNCTIONAL GAMMA-SECRETASE INHIBITORS REDUCE BETA-AMYLOID PEPTIDE LEVELS IN BRAIN", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 76, no. 1, January 2001 (2001-01-01), pages 173 - 181, XP001147446, ISSN: 0022-3042 *
NEUROBIOLOGY OF AGING 1998 UNITED STATES, vol. 19, no. 3, 1998, pages 201 - 204, ISSN: 0197-4580 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30TH ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 04-09, 2000, pages Abstract No. - 763.13, ISSN: 0190-5295 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, 31ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 10-15, 2001, pages 1718, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
CA2437480A1 (fr) 2002-08-15
EP1366061A2 (fr) 2003-12-03
WO2002062824A3 (fr) 2002-11-21
WO2002062824A2 (fr) 2002-08-15

Similar Documents

Publication Publication Date Title
IL159771A0 (en) Combinations for the treatment of inflammatory disorders
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
IL209842A0 (en) Compounds for the treatment of metabolic disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
HUP0200495A2 (en) Method of treating eating disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
IL141263A0 (en) Methods for treatment of neurological disorders
GB9908175D0 (en) Method of treating neurological disorders
EP1366061A4 (fr) Methode de traitement de troubles de la maturation du precurseur de la proteine beta amyloide
HUP0302739A3 (en) Method for the treatment of tobacco
AU2002229452A1 (en) Method of treating neurological disorders using acetone derivatives
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
AU3757300A (en) Method of treating anxiety disorders
EP1389105A4 (fr) Methode de traitement
IL155874A0 (en) Treatment of anxiety disorders
IL155769A0 (en) Method for the treatment of inflammation
IL140540A0 (en) Treatment of anxiety disorders
GB0112216D0 (en) Method of treatment
IL162053A0 (en) Method for the treatment of bone disorders
GB0118892D0 (en) Method of treatment
AU2002229795A1 (en) Method for treating sexual disorders
AU2002229796A1 (en) Method for treating sleep disorders
AU2003216501A8 (en) Methods of treating pin1 associated disorders
AU2002237894A1 (en) Methods of treating neurological disorders
GB0002973D0 (en) Method of screening for an agent for treating insulin-related disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030903

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RTI1 Title (correction)

Free format text: METHOD OF TREATING AMYLOID BETA PRECURSOR DISORDERS

A4 Supplementary search report drawn up and despatched

Effective date: 20060314

17Q First examination report despatched

Effective date: 20061031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070904